Praxis Precision Medicines
Praxis Precision Medicines' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$249 million. The diluted share count rose 25.7%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Praxis Precision Medicines does
Praxis Precision Medicines is a biopharmaceutical company that is developing drugs for brain disorders. It focuses on conditions where nerve cells in the brain are too excited or not inhibited enough, which is the problem in some genetic forms of epilepsy. It has no approved products and no product sales.
It works through two drug-discovery platforms. One, called Cerebrum, develops small-molecule pills aimed at ion channels, the gates that control nerve-cell signals. The other, called Solidus, develops antisense oligonucleotides, which are short strands of genetic material meant to turn the activity of a gene up or down. The company has four drug candidates in clinical trials, for movement disorders and epilepsy. Its most advanced program, ulixacaltamide, is being developed for essential tremor, a condition that causes shaking. Others include relutrigine and elsunersen, aimed at severe early-onset epilepsies caused by changes in the SCN2A gene and related genes.
Because it has no products to sell, the company pays for its research and trials with money it raises. A partner, UCB, has taken a license to one of its earlier candidates.
Its biggest risks, as it describes them
- It has lost money since it began and may need more funding, and may be unable to raise it.
- It has no approved products, and its drug candidates may fail in trials or be refused approval.
- Its drugs may cause side effects, or enrolling patients in trials may prove slow.
- Early or partial trial results it announces may change as more data come in.
- The markets for its drug candidates may turn out to be smaller than it expects.
Income statement
Praxis Precision Medicines lost money in fiscal 2025: a net loss of $303 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 276 | 100 | 81 | 470 | 926 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 7.5x | 3.2x | 5.4x | 10.8x | 10.2x |
| Quick ratio | 7.5x | 3.2x | 5.4x | 10.8x | 10.2x |
Cash flow
Projections
Project Praxis Precision Medicines' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Praxis Precision Medicines shares on the open market, and 3 insiders sold $11.1 million, $3.6 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 24, 2026 | Jill DeSimoneDirector | Sold plan | 11,600 | $311.32 | $3.6 million | Form 4 |
| Nov 20, 2025 | Alex NemiroffGeneral Counsel and Secretary | Sold | 25,130 | $193.08 | $4.9 million | Form 4 |
| Nov 20, 2025 | Lauren MastrocolaPrincipal Accounting Officer | Sold | 13,600 | $192.08 | $2.6 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | −1,291.0% | — |
| Altman Z'' | −24.74 | 8.97 | 12.98 |
| Accruals ratio | −12.0% | −17.9% | −7.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Praxis Precision Medicines side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Praxis Precision Medicines | FY25 | −100.0% | — | — | — | — | — | |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
| Alkermes | FY25 | −5.2% | 17.2% | 32.5% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | 0 | 2 | 9 | 0 |
| Revenue growth | — | — | — | — | — | 249.5% | −100.0% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 30 | 45 | 120 | 155 | 87 | 152 | 267 |
| Operating income | −36 | −62 | −167 | −215 | −126 | −200 | −326 |
| Net income | −36 | −62 | −167 | −214 | −123 | −183 | −303 |
| Diluted EPS (US$) | −399.00 | −117.90 | −59.10 | −69.65 | −18.69 | −10.21 | −13.48 |
| Diluted shares (millions) | 0 | 1 | 3 | 3 | 7 | 18 | 22 |
| Cash flow | |||||||
| Cash from operations | −33 | −53 | −125 | −185 | −111 | −132 | −249 |
| Capital expenditure | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | −34 | −53 | −126 | −185 | −111 | −132 | −249 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 5 | 23 | 29 | 25 | 41 | 34 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 45 | 297 | 276 | 100 | 81 | 470 | 926 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 48 | 303 | 293 | 115 | 88 | 483 | 938 |
| Total liabilities | 8 | 16 | 42 | 39 | 18 | 38 | 60 |
| Shareholders' equity | −81 | 288 | 251 | 76 | 70 | 445 | 878 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −5,164.4% | −2,340.3% | — |
| Net margin | — | — | — | — | −5,037.9% | −2,137.5% | — |
| Free cash flow margin | — | — | — | — | −4,543.8% | −1,540.5% | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −1,291.0% | — |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −59.9% | −62.1% | −130.9% | −169.1% | −71.0% | −45.8% |
| Return on assets | — | −35.2% | −56.1% | −105.0% | −121.4% | −64.0% | −42.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — |